BMS scores an early victory in the new cancer biomarker battle
pharmaphorum media | October 16, 2017
This is a measurement of the quantity of mutations carried by a tumour – and it is thought that cancer cells with a high TMB may have more antigens that could be targeted by cancer immunotherapies. Cancer cells with high TMB tend to have acquired, or somatic mutations, that have developed as the disease has progressed, rather than the genetic fault that caused the disease in the first place.